Puerain

Other Names

7,4'-Dihydroxy-8-C-glucosylisoflavone7,4'-Dyhydroxy-8-β-D-C-glycosylisoflavone7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one8-β-D-glucopyranosyl-4',7-dihydroxyisoflavoneBidarikandDaidzein-8-C-glucosideDolichos hirsutus Thunb.Dolichos lobatus Willd.Dolichos stipulaceus Lam.Fen KeFengeGalGan GeGe GenGegenIndian kudzuJapanese arrowrootKakkonKudsuKudzuKudzu rootKudzu vineKuzuKwaao KhrueaMealy kudzuNeustanthus chinensis Benth.Pachyrhizus thunbergianus Siebold & Zucc.Phaseolus lobatus (Willd.) Roxb. ex Wight & Arn.Pueraria hirsuta (Thunb.) Matsum.Pueraria lobata (Willd.) OhwiPueraria lobata var. chinensis (Benth.) OhwiPueraria montana var. lobataPueraria pseudohirsuta Tang & F.T.WangPueraria thomsonii Benth.Pueraria thunbergiana (Siebold & Zucc.) Benth.Pueraria triloba (Houtt.) MakinoPuerariae Lobatae RadixPuerariae thomsonii RadixPuerarinRadix PuerariaeVidarikandVigne KudzuYege

Synopsis

Puerarin

1. Identity: Chemical and Botanical Profile

1.1 Chemical Names and Structure

Puerarin is a bioactive isoflavone glycoside, chemically known as 8-C-glucopyranosyl daidzein or 7,4′-dihydroxyisoflavone-8-β-glucopyranoside, with the molecular formula C₂₁H₂₀O₉. It is also systematically named 8-(β-D-glucopyranosyl)-4′,7-dihydroxyisoflavone, and its CAS registry number is 3681-99-0. Structurally, puerarin is the 8-C-glucoside of daidzein. At positions 7 and 4′, there are hydroxy group substitutions, and at position 8, it is accompanied by a beta-D-glucopyranosyl residue through a C-glycosidic linkage. This C-C glycosidic bond at the 8-position is a defining structural feature: this bond distinguishes puerarin from most other flavone glycosides and contributes to puerarin's stability and bioavailability. Its molecular weight is approximately 416.38 g/mol.

In its pure isolated form, puerarin is a white crystal extracted from the roots of the kudzu plant or the kudzu vine. It appears as a white to light-yellow crystalline powder, is soluble in methanol and freely soluble in ethanol but only slightly soluble in water, and has a melting point of 187–189 °C.

1.2 Natural Sources and Botanical Origin

Puerarin is primarily isolated from the roots of the kudzu plant (Pueraria lobata), where it represents the major isoflavone component. This perennial vine in the Fabaceae family accumulates puerarin predominantly in its tuberous roots. Commonly known as kudzu, it is a vigorous, perennial climbing vine native to East Asia, including regions of China, Japan, and Korea. As the major isoflavone in Puerariae Lobatae Radix (kudzu root), puerarin typically constitutes 1.58–7.68% of the dry root weight, amounting to up to approximately 60% of total isoflavones.

Puerarin has also been reported to be extractable from Pueraria thomsonii, Pueraria omeiensis, Pueraria edulis, and Pueraria phaseoloides, though the content of puerarin differs across species. Puerarin can also be isolated from several leguminous plants of the genus Pueraria, such as Pueraria tuberosa (Willd.) and Pueraria thomsonii Benth. It can also be isolated from the tuberous root and leaves of Pueraria mirifica; the net yield of total isoflavonoids from the P. mirifica tuber (80.67 ± 4.11 mg/100 g powder) was double the yield from the P. mirifica leaves (41.68 ± 4.01 mg/100 g powder).

The genus Pueraria is taxonomically identified by puerarin itself, which serves as its chemotaxonomic marker. The kudzu root contains three prominent isoflavones: daidzein, daidzin, and puerarin. The dried root of P. thomsonii is also known as thomson kudzuvine root (Fengen) and is used extensively in southern Chinese cuisines, whereas the dried root of P. lobata is employed as the major source for therapeutic applications.

1.3 Biosynthesis

Puerarin's biosynthesis occurs via the phenylpropanoid pathway in Pueraria species, starting from phenylalanine and involving enzymes such as phenylalanine ammonia-lyase, cinnamate-4-hydroxylase, and isoflavone synthase, culminating in the attachment of a β-D-glucopyranosyl group at the 8-position through C-glycosylation.

1.4 Common Forms and Preparations

Puerarin is available in several forms for research, clinical, and supplement use. In China, the injection form of puerarin, including Puerarin Injection, Puerarin and Glucose Injection, as well as Puerarin and Sodium Chloride Injection, has been approved as a vasodilator. Oral supplement forms include standardized root extracts in capsule or tablet form. Puerarin is extracted from kudzu roots using methods such as ultrasound-assisted or supercritical fluid extraction, with analytical techniques such as high-performance liquid chromatography (HPLC) used for characterization. Since the first isolation in the late 1950s, various separation and purification techniques have been developed, including agar gel microspheres, high-speed counter-current chromatography, and chelate complex chromatography, achieving extraction purities as high as 98%.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

The tea of Radix Puerariae was first recorded in the Chinese materia medica Shen Nong Ben Cao Jing (Pharmacopeia of Shen Nong, ~200 BC) and used as an antipyretic, antidiarrhetic, diaphoretic, and antiemetic agent. In traditional Chinese medicine, the root of Pueraria montana var. lobata, known as ge gen or Radix Puerariae, has been used for centuries to treat conditions such as fever, acute dysentery, diarrhea, diabetes, and cardiovascular diseases, with puerarin identified as a key isoflavone contributing to its antipyretic and antidiabetic effects. The plant has traditionally been used in TCM for treating cardiovascular diseases and type 2 diabetes mellitus, and has been utilized as a food source, fodder, and medicine for thousands of years.

Over the centuries, kudzu root has also been used to treat alcoholism, hangover, gastric distress, high blood pressure and other circulatory problems, colds, flu, diabetes, skin rashes, kidney disease, and diabetic retinopathy. The Chinese herbal text written by Li Shih Chen recorded its use as an antiemetic, antitoxic agent for countering the effects of alcohol abuse, anti-stress agent, and remedy for neck stiffness, hypohidrosis, migraines, hypoglycemia, and certain cardiovascular diseases. Pueraria has traditionally been considered of great value for nutrition and medicine in China, and was sometimes called "the south ginseng of China."

2.2 Japanese and Korean Traditional Use

In Japanese traditional practices, the plant, referred to as kuzu, is employed in sobering beverages to alleviate alcohol intoxication and as a starch-based remedy for digestive issues like indigestion and colds. Similarly, in Korean folk medicine, it is known as gal and utilized as a digestive aid to strengthen the stomach and intestines.

2.3 Ayurvedic and South Asian Traditions

A related species, Pueraria tuberosa, known as Indian Kudzu, is known in Ayurveda as vidari (vidari kand). The tuber of this plant is widely used in the treatment of fever, menorrhagia, skin diseases, wounds, bronchial asthma, and jaundice.

2.4 Use in Thailand and Introduction to the West

Kudzu has been used in Thai folklore medicine for its rejuvenating qualities in aged women and men for nearly one hundred years. Introduced into the United States in 1876 and heavily promoted to prevent soil erosion in the 1930s and 1940s, kudzu has a tradition of use as an herbal medicine in North America, most notably for conditions related to alcohol consumption.

2.5 Scientific Identification of Puerarin

In 1959, Japanese chemist Shibata Shoji first studied the chemical constituents of pueraria root, indicating that isoflavones are the main active ingredients, including puerarin, daidzin, and daidzein. Since that initial isolation, puerarin has been the subject of extensive pharmacological research.

3. Key Constituents and Phytochemistry of the Source Plant

Kudzu root contains a diverse array of phytochemicals beyond puerarin. The kudzu plant has compounds like flavonoids, saponins, xanthones, lignans, sterols, and other compounds. Chemical analysis suggests isoflavonoids, including puerarin, daidzin, daidzein, and genistin, are the major constituents in P. thomsonii. However, 3-hydroxypuerarin and 3′-methoxypuerarin, which are normally found in P. lobata, are absent in the water extract of P. thomsonii. Puerarin itself is structurally a phytoestrogen: it serves as a key phytoestrogen due to its structural similarity to estrogen, enabling it to bind estrogen receptors and exhibit both estrogenic and antiestrogenic effects across various tissues.

4. Active Compounds and Mechanisms of Action

4.1 Phytoestrogenic Activity

Puerarin exhibits phytoestrogenic properties, interacting with estrogen receptors in a manner similar to, yet distinct from, endogenous estrogens. It has been suggested that isoflavones, belonging to the phytoestrogen group of compounds, act similarly to selective estrogen receptor modulators (SERMs). Because of its estrogenic activity, puerarin can regulate apoptosis through the estrogen receptor-dependent PI3K/Akt pathway.

4.2 Anti-inflammatory Mechanisms

The efficacy of puerarin may be mainly mediated by modulation of Na⁺, K⁺ and Ca²⁺ channels, NF-κB, PI3K/Akt, BCL-2, and BAX, as well as regulation of other targets such as PPAR, AMPK, AT1, ACE2, Nrf2, TNF-α, IL-8, COX-2, and P2X3. Pretreatment with puerarin attenuates the inflammatory response in rats, which is accompanied by Janus-activated kinase 2 (JAK2) and STAT3 activation and NF-κB inhibition. These findings suggest that the anti-inflammatory mechanisms of puerarin are mediated by blocking NF-κB signaling and inhibiting TNF-α levels. The compound also suppresses lipopolysaccharide-mediated activation of NF-κB in RAW 264.7 macrophages at concentrations of 20–40 μM.

4.3 Antioxidant Mechanisms

In a mouse model of colitis, the protein expression of Nrf2 and downstream antioxidants such as HO-1 and NQO1 were decreased but significantly increased in the model supplemented with puerarin, suggesting puerarin exerts antioxidant effects by regulating the Nrf2 pathway and antioxidant enzymes. Treatment with puerarin reduced the levels of malondialdehyde and restored glutathione levels when facing oxidative stress. The antioxidant and anti-inflammatory properties of puerarin provide the basis for its comprehensive biological effects.

4.4 Vasodilatory and Endothelial Mechanisms

Puerarin phosphorylates eNOS at the Ser1177 site in human endothelial cells to produce nitric oxide (NO), which in turn protects endothelial cells. Puerarin enhances vasodilation and insulin-stimulated Akt/eNOS pathways by inhibiting the NF-κB inflammatory pathway and decreasing plasma TNF-α levels. Puerarin treatment decreases myocardial apoptosis, prevents arrhythmia, and improves myocardial ischemia in diabetic rats; these therapeutic effects were closely associated with increased eNOS expression, NO production, and antioxidant molecule SOD expression alongside decreased inflammatory TNF-α1 expression.

4.5 Metabolic and Gut-Mediated Biotransformation

Puerarin is biotransformed by intestinal bacteria to yield the phytoestrogens daidzein and equol, resulting in antithrombotic, antiallergic, and other downstream effects. The major isoflavone in kudzu is puerarin, which is the C8-glucoside of daidzein, and puerarin is metabolized to daidzein by intestinal bacteria.

4.6 Cardioprotective Mechanisms

Preclinical evidence demonstrates that puerarin exerts cardioprotective effects against myocardial ischemia-reperfusion injury (MIRI) through multi-target mechanisms, including mitigating oxidative stress, suppressing inflammation, and inhibiting cardiomyocyte apoptosis. Puerarin can protect injured myocardium after MIRI by inhibiting NLRP3/caspase-1/GSDMD-mediated pyroptosis.

4.7 Neurological Mechanisms

The PI3K/Akt signal pathway is a crucial signal transduction mechanism that regulates biological processes such as cell regeneration, apoptosis, and cognitive memory in the central nervous system; accumulating evidence suggests that puerarin's neuroprotective effect may be related to regulation of this pathway. LPS-induced overproduction of nitric oxide (NO) and increased intracellular reactive oxygen species (ROS) in microglial cells were inhibited by puerarin; puerarin suppressed overexpression of inducible nitric oxide synthase (iNOS) through modulating MAPK phosphorylation and NF-κB signaling.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Disease

Emerging studies over the past few decades have shown that puerarin plays a critical role in protecting humans and animals from cardiovascular diseases (CVDs), including atherosclerosis, cardiac hypertrophy, heart failure, diabetic cardiovascular complications, myocardial infarction (MI), stroke, and hypertension. Due to these cardiovascular protective effects, puerarin has been developed for clinical use; Puerarin Injection, Puerarin and Glucose Injection, and Puerarin and Sodium Chloride Injection have been approved as clinical drugs.

Angina pectoris / Coronary artery disease: A published study investigated the effects of puerarin on vascular endothelial function and inflammatory factors in coronary artery disease (CAD) patients with stable angina pectoris (SAP). Meta-analyses and systematic reviews of small randomized clinical trials in ischemic stroke and unstable angina pectoris indicate that puerarin is a promising herbal medicine for the prevention or treatment of cardiovascular and cerebrovascular disorders.

Ischemic stroke: A systematic literature search identified 35 randomized controlled trials (RCTs) with a total of 3,224 participants evaluating puerarin injection for acute ischemic stroke. The combined results of 32 trials indicated that puerarin injection was better than control drugs at the clinical effective rate (RR 1.22, 95% CI 1.17 to 1.28, p < 0.001), and 16 studies showed that neurological deficit was significantly improved (MD −3.69, 95% CI −4.67 to −2.71, p < 0.001); hemorheology index and fibrinogen were significantly lower with puerarin injection compared with western conventional medicines. A separate meta-analysis of 35 RCTs showed that puerarin injection can improve neurological defects and reduce blood viscosity in patients with cerebral ischemia, with clinical effectiveness better than aspirin. Important caveat: It was suggested that puerarin injection might be more effective in the clinical treatment of acute ischemic stroke with relative safety; nevertheless, the current evidence was not adequate in virtue of poor methodological quality and insufficient safety data.

Chronic heart failure (CHF): In a meta-analysis on puerarin injection as adjunctive therapy for CHF, the incidence of adverse reactions in the puerarin group was 1.62% (11 out of 676); reported reactions included headache, gastrointestinal reactions, and respiratory reactions; no serious adverse events were reported. However, the quality of the included RCTs was rated as LOW, and the authors concluded that further high-standard clinical research is needed.

Preclinical (animal/in vitro) evidence: Despite consistent preclinical efficacy, well-designed, multicenter, large-sample, randomized controlled trials are required to evaluate the efficacy and adverse effects of puerarin in the treatment of ischemic cardiomyopathy, and well-designed clinical trials are needed to validate its translational potential and safety in humans.

5.2 Diabetes and Metabolic Disease

Despite puerarin's anti-tumor and anti-virus effects and its efficacy in improving cardiovascular or cerebrovascular diseases and preventing osteoporosis, it has also been shown to protect against diabetes and its complications. Insulin resistance and defective β-cell secretions are the main links in the pathogenesis of diabetes; puerarin's molecular mechanisms of glucose-lowering appear to act on target organs including the pancreas, liver, skeletal muscle, and adipose tissue.

Diabetic peripheral neuropathy (DPN): A systematic review and meta-analysis of 53 randomized controlled trials evaluated the efficacy and safety of puerarin injection for the treatment of diabetic peripheral neuropathy. Puerarin injection for the treatment of DPN could significantly increase the probability of sensory nerve conduction velocity and motor nerve conduction velocity. Pharmacological studies confirmed that puerarin injection can lower blood sugar, significantly improve microcirculation, expand the coronary arteries, and reduce platelet aggregation; puerarin injection has been widely used for more than 20 years in China for this indication.

Diabetic kidney disease: Puerarin treatment of diabetic eNOS-knockout mice significantly attenuated albuminuria and diabetic kidney injury, associated with reduced oxidative stress and reduced NADPH oxidase 4 (NOX4) in glomeruli; in podocytes cultured in high glucose conditions, puerarin reduced superoxide production and NOX4 expression, and increased SIRT1-mediated deacetylation of NF-κB. These findings are from animal and cell studies; comparable human clinical trial evidence is not yet established.

5.3 Alcohol Use and Dependence

The use of kudzu root preparations to reduce alcohol consumption has one of the longest documented histories and has been examined in human clinical trials to a greater degree than most other puerarin applications.

Human pilot trial: A pilot study described as the first demonstration that a single isoflavone—puerarin—found in kudzu root can reduce human alcohol consumption and alter drinking patterns during a laboratory simulation of a binge drinking opportunity was published in 2012. Participants consumed on average 3.5 (±0.55) beers when treated with placebo and 2.4 (±0.41) beers when treated with puerarin. Participants who received 1,200 mg of puerarin per day consumed less alcohol and took more time to consume each drink compared to control subjects. This reduction was statistically significant (p = 0.043), and similar significant reductions were observed in total consumption weight.

Participants continued to report typical alcohol effects; subjective reports of feeling "drunk" or "floating" were elevated by alcohol consumption and were not altered by puerarin treatment, and there was no evidence that dysphoric alcohol effects increased (e.g., nausea, dizziness, feeling terrible). The mechanism of action for puerarin's antidipsotropic effect is unknown. Although the study was not specifically designed to assess daily drinking, analysis of daily diary entries suggested that puerarin reduced daily drinking during the active medication week, consistent with a 4-week outpatient study conducted with kudzu root which found a 50% reduction of daily drinking overall, and a significant increase in abstinent days.

Animal evidence: In alcohol-preferring (P) rats, a daily 50 mg/kg dose of puerarin caused approximately 50% suppression in alcohol intake, but did not affect body weight or food and total fluid intake.

Evidence assessment: The human evidence for puerarin's effects on alcohol consumption is limited to small, short-duration pilot studies. While the direction of effects is consistent across trials, larger and longer-duration RCTs are required before strong conclusions can be drawn.

5.4 Osteoporosis and Bone Health

A systematic review and meta-analysis evaluated the anti-osteoporotic efficacy of puerarin in rodent models of osteoporosis. Twenty-eight studies involving 570 animals were included; the meta-analysis demonstrated that puerarin significantly increased femoral bone mineral density (BMD) (SMD = 2.95, 95% CI: 2.32 to 3.58, p < 0.00001) and improved bone microarchitecture by increasing BV/TV, Tb.Th, and Tb.N, and decreasing trabecular separation. Subgroup analysis revealed that the most pronounced BMD improvement occurred at doses ≥50 mg/kg/day administered for ≥8 weeks. These results, however, are exclusively from animal models.

Clinical exploratory trial (menopausal women): A clinical trial evaluated the efficacy on bone and cartilage turnover, menopausal symptoms, and safety of five dose regimens of kudzu root extract administered either once, twice, or three times daily in women with at least mild menopausal symptoms; 50 postmenopausal women were randomized equally into five different dose regimen groups in a four-week, parallel-group, open-label, single-center, exploratory study. The product contained 13.4 g puerarin per 100 g, corresponding to 37.5 mg puerarin per capsule; the lowest total daily dose of three capsules was equivalent to 0.84 g of kudzu extract (113 mg puerarin), and the maximum daily dose of nine capsules corresponded to 2.52 g (338 mg of puerarin). Though kudzu root has been used for many years in traditional Chinese medicine, evidence regarding dose regimens, their pharmacological profile, effect on bone and cartilage turnover, and potential to treat menopausal symptoms of kudzu extracts is limited.

5.5 Neuroprotection and Neurological Disease

Experimental and clinical studies have reported that puerarin has been used in the treatment of cardiovascular disease, diabetes mellitus and its complications, cancer, osteoporosis, nonalcoholic fatty liver, and endometriosis; in recent years, puerarin has attracted much attention because of its neuroprotective effects in Alzheimer's disease (AD), Parkinson's disease (PD), and other central nervous system diseases. Puerarin has potent neuroprotective effects due to its excellent anti-inflammatory, antioxidant, and anti-apoptotic properties.

Clinical studies have shown that puerarin inhibits the increase of IL-6 after acute ischemic stroke and reduces lactate dehydrogenase levels following ischemia/reperfusion; puerarin in combination with aspirin treatment for acute cerebral infarction has protective effects on damaged vascular endothelial cells. The bulk of neuroprotection evidence, however, remains at the level of preclinical (cell culture and animal) studies; large-scale, well-designed human RCTs specifically for neurodegenerative conditions have not been established.

5.6 Hepatoprotection and Liver Disease

Puerarin, the main component extracted from pueraria, has a variety of pharmacological characteristics; in recent years, puerarin has received increasing attention for its significant hepatoprotective effects, such as metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and hepatic carcinoma. Its pharmacological effects on various liver diseases operate through multiple mechanisms, including modulation of inflammation factors, oxidative stress, lipid metabolism, apoptosis, and autophagy. Puerarin demonstrates therapeutic efficacy across various liver diseases by targeting key biochemical pathways; studies show it effectively modulates lipid levels, reduces oxidative stress, induces autophagy, and decreases inflammation. The majority of this evidence currently derives from animal and in vitro models rather than large-scale human trials.

5.7 Anticancer Activity

Puerarin has been demonstrated to have potential anti-tumor effects via induction of apoptosis and inhibition of proliferation. In pancreatic cancer cell studies, puerarin treatment significantly repressed cell proliferation; puerarin induced mitochondrial-dependent apoptosis by causing a Bcl-2/Bax imbalance; and puerarin inhibited cell migration and invasion by antagonizing epithelial-mesenchymal transition (EMT). These findings are from in vitro (cell culture) and animal xenograft models. No human clinical trial data currently support puerarin as an anticancer treatment.

6. Pharmacokinetics and Bioavailability

Puerarin has poor solubility due to its large conjugated skeleton, with a solubility of only 1.1 × 10⁻² % mol/L in water, resulting in low oral bioavailability of approximately 7%. According to the biopharmaceutics classification system (BCS), puerarin can be classified as a class IV drug due to its low solubility and limited intestinal permeability. Puerarin has poor water-solubility and liposolubility owing to its chemical structure, leading to poor oral absorption, low bioavailability, and lower blood concentration after oral administration.

In animal models, puerarin reaches maximum plasma concentration (Cmax) at 0.45–5.00 hours post-dose, with an absorption half-life of 0.80–1.00 hours and a distribution coefficient of 1.95. When administered intravenously, puerarin is widely distributed in the hippocampus, mammary gland, liver, kidneys, spleen, stomach, tibia, and femur.

The chemical structure of puerarin leads to low solubility and permeability, which results in poor oral absorption and low bioavailability. To overcome this obstacle, by modifying the structure of puerarin, a number of derivatives with better bioavailability have been developed, such as P1-EA, P2-EA, puerarin-7-O-glucuronide and 3′-methoxy puerarin. To improve solubility of puerarin, cosolvents such as propylene glycol, ethylene glycol, and polyvinylpyrrolidone had been added to the clinical injection formulation.

7. Dosage Forms and Reported Clinical Dosages

The following dosages are reported in published studies and do not constitute recommendations.

In the human pilot study on alcohol reduction, participants received 1,200 mg of puerarin per day.
In the clinical trial on menopausal symptoms and bone/cartilage turnover, each capsule contained 37.5 mg of puerarin; the lowest daily dose regimen of three capsules corresponded to 113 mg puerarin/day, and the maximum daily dose of nine capsules corresponded to 338 mg of puerarin/day.
In a rat study on diabetic osteoporosis, puerarin was administered by injection at 100 mg/kg/day for 6 weeks.
In the alcohol-preferring rat model, a daily dose of 50 mg/kg of puerarin caused approximately 50% suppression in alcohol intake.
In in vitro studies on cardiac hypertrophy in human AC16 cells, 40 μM puerarin was demonstrated to be a safe dose using CCK-8 assay.
In the meta-analysis of rodent osteoporosis studies, the most pronounced BMD improvement occurred at doses ≥50 mg/kg/day administered for ≥8 weeks.

Due to puerarin's poor water and fat solubility, oral bioavailability is approximately 7%, which often necessitates intravenous administration in clinical settings.

8. Safety Considerations and Adverse Reactions

8.1 General Safety Profile

Due to its restricted solubility, pharmacokinetic studies reveal that puerarin has a low bioavailability; however, combining puerarin with novel drug delivery systems can improve its bioavailability; meanwhile, puerarin has very low toxicity and high safety in general, providing a solid foundation for its further development. The safety and efficacy of puerarin have already been established in humans, especially in China where it is approved for intravenous injection as a vasodilator to treat coronary heart disease, myocardial infarction, and angina.

8.2 Adverse Reactions: Intravenous Administration

The most clinically significant safety concerns are specifically associated with the intravenous injection form of puerarin:

A study evaluating the safety of intravenous infusion of puerarin injection (Xie et al., 2018), reporting that adverse reactions, primarily allergic reactions and acute intravascular hemolysis, accounted for 88.3% of cases.
Analysis of 62 papers related to adverse drug reactions of puerarin injection showed that adverse drug reactions occurred mostly in patients aged 50–79 years; the immune/blood system accounted for the majority of reactions; puerarin also induced drug-induced immune hemolytic anemia; hemolysis largely limited the clinical use of puerarin injections.
Intravascular administration of puerarin can cause adverse reactions including drug fever, rash, nausea, vomiting, diarrhea, hepatic/renal damage, palpitations, anaphylactic shock, and hemolysis; hemolysis represents a key limiting factor for puerarin injection's clinical use. This hemolytic effect has been confirmed in both animal and cellular models: rabbits receiving 25 mg/kg/day puerarin developed hemolysis after 42 days, and in vitro erythrocyte experiments demonstrated that puerarin induces hemolysis in a dose- and time-dependent manner.
Cosolvents such as propylene glycol, ethylene glycol, and polyvinylpyrrolidone added to the clinical injection formulation to improve solubility have themselves caused adverse drug reactions after intravenous administration such as vascular stimulation, fever, allergy, and erythrolysis.
Adverse reactions of puerarin injection in treating acute ischemic stroke included nausea, vomiting, and other mild gastrointestinal discomfort, facial flushing, dizziness, and allergic reaction.

8.3 Dose-Related Considerations

The chemical structure of puerarin leads to low solubility and permeability, which results in poor oral absorption and low bioavailability. Simply increasing the dose will not effectively improve the bioavailability, and may lead to toxicity and side effects.

8.4 Oral Supplement Safety (Human Data)

In the human alcohol reduction study, participants continued to report typical alcohol effects; subjective reports of feeling "drunk" or "floating" were elevated by alcohol consumption and were not altered by puerarin treatment; there was no evidence that dysphoric alcohol effects such as nausea, dizziness, or feeling terrible increased during puerarin treatment. No serious adverse events were reported in this small pilot trial. Large-scale, long-duration oral safety data in humans remain limited.

8.5 Potential Drug Interactions

Puerarin has been investigated for interactions with cytochrome P450 (CYP450) enzymes. Research has noted potential for interactions with CYP2D6 and CYP1A2 activities in vivo. Further clinical trials with a larger sample size and rigorous design are needed to validate current findings in the prevention and treatment of cardiovascular diseases and to characterize interactions. Given puerarin's phytoestrogenic mechanism, it has none of the estrogenic activity of daidzin and daidzein and therefore would not be expected to present a complication for women related to those specific estrogenic pathways. Concurrent use with antidiabetic drugs, anticoagulants, and antihypertensives warrants attention, as puerarin exerts blood glucose-lowering, platelet-aggregation-inhibiting, and vasodilatory effects in preclinical and clinical models.

9. Body Systems and Health Areas Associated with Puerarin

Based on the totality of published peer-reviewed research, puerarin has been investigated in relation to the following body systems and health conditions:

Cardiovascular system: Cardioprotection, vasodilation, anti-inflammation, inhibiting alcohol intake, and attenuating insulin resistance.
Central nervous system: Neuroprotection, cerebral ischemia, Alzheimer's disease, Parkinson's disease.
Endocrine/metabolic system: Enhancing circulatory system function, reducing myocardial oxygen consumption, decreasing blood sugar, and preventing hypertension and arteriosclerosis.
Musculoskeletal system: Osteoporosis prevention and bone formation support.
Hepatic system: Metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and hepatic carcinoma.
Alcohol use behavior: Long history of use as an anti-dipsotropic agent ameliorating the effects of alcohol abuse.
Reproductive/menopausal health: The root of kudzu has a history of usage in relation to the treatment of menopausal symptoms as well as conditions affecting menopausal women.
Oncology (preclinical): Anti-tumor activity via apoptosis induction (in vitro/animal data only).

References

Health Conditions

Health conditions that Puerain may help support.

No conditions available.

Body Systems

Body systems that Puerain may help support.

No body systems available.